Ir para o conteúdo principal Ir para o menu de navegação principal Ir para o rodapé
Ciências da Saúde
Publicado: 2014-08-04

Immunologic Response to HIV Infection: Main Immunopathological Alterations

INSTITUTO DE CIÊNCIAS DA SAÚDE, UNIVERSIDADE FEDERAL DE MATO GROSSO
##plugins.generic.jatsParser.article.authorBio##
×

D. Geraldelli

INSTITUTO DE CIÊNCIAS DA SAÚDE, UNIVERSIDADE FEDERAL DE MATO GROSSO

ÃREA: FARMÃCIA

Instituto de Ciências da Saúde, Universidade Federal de Mato Grosso
##plugins.generic.jatsParser.article.authorBio##
×

L. Castoldi

INSTITUTO DE CIÊNCIAS DA SAÚDE, UNIVERSIDADE FEDERAL DE MATO GROSSO

ÃREA: IMUNOLOGIA

HIV infection immune response AIDS CD4 T cells

Resumo

The intense degradation of defense cells caused by the human immunodeficiency virus (HIV) in an organism and the speed at which the viral genome mutates to escape the initial immune response are the prime difficulties in combating opportunistic diseases and in creating an efficient vaccine for this virus. The common opportunistic diseases observed for HIV positive patients include tuberculosis, candidiasis and toxoplasmosis. One of the risk factors is the decrease in CD4+ T-lymphocyte count and the high plasmatic viral load, rendering the organism susceptible to these pathogens. Despite the effectiveness of antiretroviral therapy, this does not provide total elimination of the virus, only eliminating the virus present in the plasma. On treatment withdrawal, the infected latent CD4+ T-cells can re-establish the infection, conferring a large barrier to definitive HIV cure. Current studies have evaluated the inhibition of class I histone diacetylase (HDAC) enzymes as a strategy to induce the viral gene expression and, consequently, the gradual emptying of latent reservoirs of the virus, improving the action of antiretroviral therapy. Thus, the monitoring of immune activation and counting of CD4+ T-lymphocytes are of fundamental importance to the prognosis of HIV patients, along with early diagnoses of opportunistic diseases, in order to avoid complications from these diseases.

Referências

  1. ALFONZO, MA., DIAZ, A., SICILIANO, L., LOPEZ, MG., HUNG, A., GARCIA, JF. Estado funcional dos linfócitos TD4+ e CD8+ e seu papel na progressão lenta da infecção por HIV em pacientes pediátricos. J. Pediatr. (Rio J.) 88: 161-168, 2012. URL: http://www.scielo.br/pdf/jped/v88n2/a11v88n2.pdf
  2. ARCHIN, NM., ESPESETH, A., PARKER, D., CHEEMA, M., HAZUDA, D., MARGOLIS, DM. Expression of latent HIV induced by the potent HDAC inhibitor suberoylanilide hydroxamic acid. AIDS Res. Hum. Retroviruses 25: 207–212, 2009. URL: http://online.liebertpub.com/doi/pdf/10.1089/aid.2008.0191
  3. ARCHIN, NM., VAIDY, NK., KURUCA, JD., LIBERTY, AL., WIEGAND, A., KEARNEY, MF., COHEN, MS., COFFIN, JM., BOSCH, RJ., GAY, CL., ERON, JJ., MARGOLIS, DM., PERELSON, AS. Immediate antiviral therapy appears to restrict resting CD4+ cell HIV-1 infection without accelerating the decay of latent infection. Proc. Natl. Acad. Sci. USA 109: 9523-9528, 2012a. URL: http://www.pnas.org/content/109/24/9523.full.pdf+html
  4. ARCHIN, NM., LIBERTY, AL., KASHUBA, AD., CHOUDHARY, SK., KURUC, JD., CROOKS, AM., PARKER, DC., ANDERSON, EM., KEARNEY, MF., STRAIN, MC., RICHMAN, DD., HUDGENS, MG., BOSCH RJ., COFFIN, JM., ERON, JJ., HAZUDA, DJ., MARGOLIS, DM. Administration of Vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature 25: 482-485, 2012. URL: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3704185/pdf/nihms383721.pdf
  5. BRASIL, Ministério da Saúde. 2013. http://bvsms.saude.gov.br.
  6. BRASIL,Ministério da Saúde.2012. http://portalsaude.saude.gov.br/portalsaude/index.html.
  7. COSSARIZZA, A., BERTONCELLI, L., NEMES, E., LUGLI, E., PINTI, M., NASI, M., DE BIASI, S., GIBELLINI, L., MONTAGNA, JP., VECCHIA, M., MANZINI, L., MESCHIARI, M., BORGHI, V., GUARALDI, G., MUSSINI, C. T cell activation but not polyfunctionality after primary HIV infection predicts control of viral load and length of the time without therapy. Public Library of Science 7: 1-12, 2012. URL: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3517542/pdf/pone.0050728.pdf
  8. ERIKSSON, EM., KEH, CE., DEEKS, SG., MARTIN, JN., HECHT, FM., NIXON, DF. Differential expression of CD96 surface molecule represents CD8+ T cells with dissimilar effector function during HIV-1 infection. Public Library of Science 7: 1-8, 2012. URL: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3521672/pdf/pone.0051696.pdf
  9. JAMAL, LF., MOHERDAUI, F. Tuberculose e infecção pelo HIV no Brasil: magnitude do problema e estratégias para o controle. Rev. Saúde Pública 41: 104-110, 2007. URL: http://www.scielo.br/pdf/rsp/v41s1/6545.pdf
  10. JIANG, Y., CUI, X., CUI, C., ZHANG, J., ZHOU, F., ZHANG, Z., FU, Y., XU, J., CHU, Z., LIU, J., HAN, X., LIAO, C., WANG, Y., CAO, Y., SHANG, H. The function of CD3+CD56+NKT cells in HIV-infected individuals. BioMed Research Internacional 2014: 1-9, 2014. URL: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3977420/pdf/BMRI2014-863625.pdf
  11. KHAN, KH. DNA vaccines: roles against diseases. Germs. 3: 26-35, 2013. URL: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3882840/pdf/germs-03-01-026.pdf
  12. KLEIN, F., MOUQUET, H., DOSENOVIC, P., SCHEID, JF., SCHARF, L., NUSSENZWEIG, MC. Antibodies in HIV-1 vaccine development and therapy. Science 341: 1199-1204, 2013. URL: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3970325/pdf/nihms560651.pdf
  13. LIU, MK., HAWKINS, N., RITCHIE, AJ., GANUSOV, VV., WHALE, V., BRACKENRIDGE, S., LI, H., PAVLICEK, JW., CAI, F., ROSE-ABRAHAMS, M., TREURNICHT, F., HRABER, P., RIOU, C., GRAY, C., FERRARI, G., TANNER, R., PING, LH., ANDERSON, JA., SWANSTROM, R.; CHAVI, CB., COHEN, M., KARIM, SS., HAYNES, B., BORROW, P., PERELSON, AS., SHAW, GM., HAHN, BH., WILLIAMSON, C., KORBER, BT., GAO, F., SELF, S., MCMICHAEL, A., GOONETILLEKE, N. Vertical T cell immunodominance and epitope entropy determine HIV-1 escape. The Journal of Clinical Investigation 123: 380-393, 2013. URL: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3533301/pdf/JCI65330.pdf
  14. MATALON, S., RASMUSSEN, TA., DINARELLO, C A. Histone deacetylase inhibitors for purging HIV-1 from the latent reservoir. Mol. Med. 17: 466 -472, 2011. URL: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3105138/pdf/11_76_matalon.pdf
  15. MCMICHAEL, AJ., BORROW, P., TOMARAS, GD., GOONETILLEKE, N., HAYNES, BF. The immune response during acute HIV-1 infection: clues for vaccine development. Nat. Rev. Immunol. 10: 11-23, 2010. URL: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3119211/pdf/nihms300023.pdf
  16. MIZIARA, ID., LIMA, AS., LA CORTINA, AC. Candidíase oral e leucoplasia pilosa como marcadores de progressão da infecção pelo HIV em pacientes brasileiros. Rev. Bras. Otorrinolaringol. 70: 310-314, 2004. URL: http://www.scielo.br/pdf/rboto/v70n3/a05v70n3.pdf
  17. OLIVEIRA, PM., MASCARENHAS, RE., FERRER, SR., OLIVEIRA, RPC., TRAVESSA, IEM., GOMES, MVC., GRASSI, MFR. Vulvovaginites em mulheres infectadas pelo vírus da imunodeficiência humana. Rev. Bras. Ginecol. Obstet. 30: 121-126, 2008. URL: http://www.scielo.br/pdf/rbgo/v30n3/3170.pdf
  18. OLIVETTA, E., TIRELLI, V., CHIOZZINI, C., SCAZZOCCHIO, B., ROMANO, I., ARENACCIO, C., SANCHEZ, M. HIV-1 Nef Impairs Key Functional Activities in Human Macrophages through CD36 Downregulation. PLOS ONE 9: 1-21, 2014. URL: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3976297/pdf/pone.0093699.pdf
  19. PACE, M.J, GRAF, EH., AGOSTO, LM., MEXAS, AM., MALE, F., BRADY, T., BUSHMAN, FD., O'DOHERTY, U. Directly infected resting CD4+ T cells can produce HIV Gag without spreading infection in a model of HIV latency. Public Library of Science Pathogens 8: 2012. URL: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3406090/pdf/ppat.1002818.pdf
  20. PEREIRA, CCA., MACHADO, CJ., RODRIGUES, RN. Perfis de causas múltiplas de morte relacionadas ao HIV/AIDS nos municípios de São Paulo e Santos, Brasil, 2001. Cad. Saúde Pública. 23: 645-655, 2007. URL: http://www.scielo.br/pdf/csp/v23n3/23.pdf
  21. RASMUSSEN, TA., SCHMELTZ SØGAARD, O., BRINKMANN, C., WIGHTMAN, F., LEWIN, SR., MELCHJORSEN, J., DINARELLO, C., ØSTERGAARD, L., TOLSTRUP, M. Comparison of HDAC inhibitors in clinical development; effect on HIV production in latently infected cells and T-cell activation. Hum. Vaccin. Immunother. 9: 993-1001, 2013. URL: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3899169/pdf/hvi-9-993.pdf
  22. SANTOS, ES., ARAUJO, AF., GALVAO-CASTRO, B., ALCANTARA, LCJ. Diversidade genética do vírus da imunodeficiência humana tipo 1 (HIV-1) em mulheres infectadas de uma cidade do nordeste do Brasil. Rev. Bras. Ginecol. Obstet. 31: 609-614, 2009. URL: http://www.scielo.br/pdf/rbgo/v31n12/v31n12a06.pdf
  23. TASCA, KI., CALVI, SA., SOUZA, LR. Immunovirological parameters and cytokines in HIV infection. Rev. Soc. Bras. Med. Trop. 45: 663-669, 2012. URL: http://www.scielo.br/pdf/rsbmt/v45n6/02.pdf

Como Citar

Geraldelli, D., & Castoldi, L. (2014). Immunologic Response to HIV Infection: Main Immunopathological Alterations. Scientific Electronic Archives, 8(1), 87–92. https://doi.org/10.36560/812015121